Majdic O, Bettelheim P, Stockinger H, Aberer W, Liszka K, Lutz D, Knapp W
Int J Cancer. 1984 May 15;33(5):617-23. doi: 10.1002/ijc.2910330511.
The selectivity of a novel myelomonocytic cell surface antigen, designated M2, has been assessed in a series of 208 leukemias. The M2 antigen is defined by a monoclonal antibody (VIM-2) of the IgM class. Its expression within the normal hemopoietic system is restricted to myelomonocytic cells. Lymphocytes, erythrocytes, thrombocytes and their morphologically recognizable precursors are negative. Sixty of the 66 acute myeloblastic leukemias (= 91%) and 28 of the 30 myeloid blast crises of CML patients (= 93%) were M2-positive. As expected from our findings with normal myeloid cells, the myeloid cells found in stable phase of CML were also in all instances, M2-positive. Quite in contrast, lymphoid cells from patients with B-CLL, T-CLL, prolymphocytic leukemia, hairy-cell leukemia, lymphoblastic lymphoma, Sézary syndrome, from CML patients in lymphoid blast crisis and from the majority of patients with ALL, were completely M2-negative. Also negative were the blast cells of patients with acute megakaryoblastic leukemia and acute erythroleukemia. A direct comparison of M2 expression with the display of the 3-fucosyl-N-acetyllactosamine determinant, the structure recognized by most of the anti-myeloid monoclonal antibodies reported so far, shows that more AMLs are M2-positive and the proportion of M2-positive blast cells in individual AML samples is higher.
在一系列208例白血病中评估了一种名为M2的新型骨髓单核细胞表面抗原的选择性。M2抗原由IgM类单克隆抗体（VIM-2）定义。其在正常造血系统中的表达仅限于骨髓单核细胞。淋巴细胞、红细胞、血小板及其形态可识别的前体细胞均为阴性。66例急性髓细胞白血病中有60例（=91%）以及30例慢性粒细胞白血病患者的髓系原始细胞危象中有28例（=93%）为M2阳性。正如我们对正常髓细胞的研究结果所预期的那样，慢性粒细胞白血病稳定期的髓细胞在所有情况下也均为M2阳性。相比之下，B细胞慢性淋巴细胞白血病、T细胞慢性淋巴细胞白血病、原淋巴细胞白血病、毛细胞白血病、淋巴母细胞淋巴瘤、Sezary综合征患者的淋巴细胞，慢性粒细胞白血病患者淋巴原始细胞危象时的淋巴细胞以及大多数急性淋巴细胞白血病患者的淋巴细胞，均完全为M2阴性。急性巨核细胞白血病和急性红白血病患者的原始细胞也为阴性。将M2表达与3-岩藻糖基-N-乙酰乳糖胺决定簇（迄今为止报道的大多数抗髓系单克隆抗体所识别的结构）的表现进行直接比较，结果显示更多的急性髓细胞白血病为M2阳性，并且在单个急性髓细胞白血病样本中M2阳性原始细胞的比例更高。
